|
Mar 21
|
3 Stocks That Could Be the Next Big Thing in Gene Editing
|
|
Feb 15
|
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
|
|
Feb 12
|
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
|
|
Jan 4
|
Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024
|
|
Jan 2
|
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 29
|
Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade
|
|
Dec 29
|
Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet
|
|
Dec 1
|
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
|
|
Nov 29
|
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
|
|
Nov 28
|
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
|
|
Nov 27
|
Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect?
|
|
Oct 10
|
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
|
|
Aug 11
|
Investors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last year
|
|
Aug 10
|
Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 10
|
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
|